Basic Information
Mana.bio is an AI-based drug delivery startup that focuses on gene therapy, including DNA and RNA-based treatments as well as vaccines. By integrating unique machine learning with lipid nanoparticle (LNP) design, Mana.bio is ushering in a new era of genetic medicine. The company is building a scalable high-throughput Design-Build-Test-Learn cycle platform to rapidly identify potential lipid nanoparticle-based drug delivery carriers for specific payloads such as RNA, DNA, and CRISPR.